Disc Medicine initiated with an Overweight at Wells Fargo

Wells Fargo analyst Tiago Fauth initiated coverage of Disc Medicine with an Overweight rating and $75 price target. The analyst says regulatory clarity for bitopertin is an important fundamental near-term driver for the shares and the Phase 3 has a higher probability of sucess than implied at current valuation levels. Disc Medicine has several catalysts throughout 2025 for the pipeline, the analyst tells investors in a research note.